FDAapproval72% confidence
FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors
Source: FDA
Why This Matters
Why this matters: sets a approval precedent in the same sub-indication (breast cancer) as AstraZeneca.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · Breast Cancer
- Sub-indication
- Breast Cancer
Related signal: Datroway Approved in EU for Metastatic TNBC as First TROP2-Directed Therapy